NCT03474497 2026-01-29UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint BlockadeUniversity of California, DavisPhase 1/2 Active not recruiting18 enrolled 13 charts
NCT04596033 2022-07-15TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell TherapyGenocea Biosciences, Inc.Phase 1 Terminated49 enrolled